CJC-1295 isn't found on pharmacy shelves in Ebly or anywhere else for that matter — it's a research compound supplied via a dedicated online market. This concentration of supply in online vendors is actually an advantage for quality — top vendors compete on lab-verified purity in ways local stores never could. What genuinely separates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety screening. The sections below cover what Ebly researchers need to know about sourcing, verifying, and handling CJC-1295 for research purposes.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Ebly researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
The first step for any Ebly researcher sourcing CJC-1295 is identifying 2-3 vendors with documented positive community reputations — commercial rankings reflect SEO budgets rather than product quality. A COA for CJC-1295 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. The combination of peer feedback and direct document verification is the most effective quality filter — community feedback surfaces systemic problems invisible in one transaction, and vice versa. For Ebly researchers making a first CJC-1295 purchase: verify the vendor against this framework, begin with a small order, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Ebly
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human use by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Proper handling of CJC-1295 requires strict sterile technique during reconstitution — alcohol-swabbed septum, fresh needles, clean working environment — and cold chain maintenance from receipt through use. The most significant preventable safety hazard in CJC-1295 research is bacterial endotoxin from low-quality material — a documented endotoxin result in your specific batch certificate is the key safeguard. Researchers running multi-compound protocols with CJC-1295 should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
